Product overview
In vitro differentiated human cardiomyocytes are an essential tool not only for general cardiovascular research but also to address key unmet needs in drug development and pre-clinical research markets:
- Cardiotoxicity is a major cause for compound failure in P2/3 clinical programs of drug development. New testing systems, such as iPSC-derived cardiomyocytes, enable the assessment of the safety pharmacology core battery at the pre-clinical stage
- The leading cause of morbidity in developed countries is cardiovascular disease. A major constraint for the development of adequate therapies has been the lack of suitable cell-based assays with physiological relevance
Axiogenesis provides well – characterized, human induced pluripotent stem (iPS) cell-derived cardiomyocytes, named Cor.4U® , which represent a highly translational and cost effective in vitro model system with key advantages:
- Predictive and physiological in vitro cell system broadly applicable drug development and preclinical research purposes
- Established model system for cardiac preclinical safety assessment, currently validated by the CiPA initiative
- Applicable for HTS since it allows for quantity, consistency and efficiency – Get your results in 3 days or less
Characterization
Beating Cor.4U Cardiomyocyte
Cor.4U composition

Manual Patch Clamp analysis of Cor.4U® cardiomyocytes. Current clamp recordings from single Cor.4U® cells show typical ventricular-, atrial- and nodal-like action potentials, demonstrating the different Cor.4U® subtypes. Cor.4U® comprises 60% ventricular cells
Assays & Applications

Extract of Impedance measurements with Cor.4U® cardiomyocytes. The data shows regular beating Cor.4U® cardiomyocytes syncytia 30h after plating. Pharmacological measurements can be performed once a stable beating is obtained.
Cor.4U® have been validated in the following assays and applications:
- Manual and automated patch clamp [ Poster 1 ] [ Poster 2 ]
- Impedance measurements [ Poster 1 ] [ Poster 2 ]
- Microelectrode array (MEA) [ Poster ]
- Calcium sensitive dyes [ Poster ]
- Voltage sensitive dyes [ Poster ]
- Cell metabolism analysis [ Poster 1 ] [ Poster 2 ]
- Organotypic 3D culture [ Video ]
- Cell contraction force
- High content analysis (e.g., hypertrophy disease modeling) [ Poster 1 ] [ Poster 2 ]
Drug testing on Cor.4U using calcium transients analysis in a HTS assay format

Heat Map of drug effects on Cor.4U® cardiomyocytes (Assay: HTS intracellular calcium transient measurement)
Ordering information
Next day delivery is available for both European and US customers.
For sales inquiries and data requests, contact us at order@axiogenesis.com.
Order Information Cor.4U
| Ax-B-HC02-MPC: | 0.25 x 10^6 frozen cells (vial) |
| Ax-B-HC02-1M: | 1.0 x 10^6 frozen cells (vial) |
| Ax-B-HC02-4M: | 4.0 x 10^6 frozen cells (vial) |
| Ax-C-HC02-APC: | 0.5 x 10^6 fresh cells (flask) |
| Ax-C-HC02-FR1 | 1 x 10^6 fresh cells (flask) |
| Ax-C-HC02-FR3 | 3 x 10^6 fresh cells (flask) |
| Ax-C-HC02-96: | fresh cells (96 well plate) |
| Ax-C-HC02-384: | fresh cells (384 well plate) |
| Ax-C-HC02-EPL: | fresh cells (96 well xCELLigence plate) |
| Ax-M-HC250: | Cor.4U@ Medium (contains FBS) |
| Ax-M-BMCC250: | Cor.4U@ Medium (without FBS) |
